The naturally occurring mannopeptimycins (formerly AC98-1 through AC98-5) are a novel class of glycopeptide antibiotics that are active against a wide variety of gram-positive bacteria. The structures of the mannopeptimycins suggested that they might act by targeting cell wall biosynthesis, similar to other known glycopeptide antibiotics; but the fact that the mannopeptimycins retain activity against vancomycin-resistant organisms suggested that they might have a unique mode of action. By using a radioactive mannopeptimycin derivative bearing a photoactivation ligand, it was shown that mannopeptimycins interact with the membranebound cell wall precursor lipid II [C 55 -MurNAc-(peptide)-GlcNAc] and that this interaction is different from the binding of other lipid II-binding antibiotics such as vancomycin and mersacidin. The antimicrobial activities of several mannopeptimycin derivatives correlated with their affinities toward lipid II, suggesting that the inhibition of cell wall biosynthesis was primarily through lipid II binding. In addition, it was shown that mannopeptimycins bind to lipoteichoic acid in a rather nonspecific interaction, which might facilitate the accumulation of antibiotic on the bacterial cell surface.
Multiply drug-resistant pathogenic bacteria continue to emerge, and this situation poses a great threat to effective antimicrobial chemotherapy and infection control. Particularly threatening is the emergence of clinical strains of Staphylococcus aureus and Enterococcus spp. that are gradually building resistance to vancomycin, often considered to be the drug of last resort. These resistance issues emphasize the importance of the development of new antibiotics that would be effective for the treatment of bacterial infections by blocking essential pathogen-specific molecular processes. These include both newly discovered processes and those already targeted by antimicrobial chemotherapy. The biosynthesis of the bacterial cell wall is unique to bacteria and thus remains an important target for the screening and development of new drugs.
The biosynthesis of peptidoglycan (PG), the major component of the bacterial cell wall, consists of three major stages. This process originates in the cytoplasm by the synthesis of the UDP-linked precursors UDP-N-acetylglucosamine (UDPGlcNAc) and a species-specific UDP-N-acetylmuramic acid (UDP-MurNAc)-peptide catalyzed by the MurA-MurF enzymes (21, 22, 32, 33, 49) . In the second stage, which is catalyzed by the membrane-bound enzymes MraY and MurG, nonnucleotide portions of the two precursors are sequentially transferred to the undecaprenylphosphate carrier, resulting in the formation of two lipid intermediates, lipid I and lipid II (19, 45, 49) . The final stage involves the incorporation of the MurNAc-peptide-GlcNAc subunit into the nascent PG chain (transglycosylation) and the subsequent attachment of the nascent PG to the preexisting cell wall by the formation of bonds between peptide chains (transpeptidation) (46, 49, 51, (53) (54) (55) . In Escherichia coli, both of these reactions are catalyzed by distinct domains of two bifunctional penicillin-binding proteins (PBPs), PBP1A and PBP1B (11, 20, 31) . However, in S. aureus the role of individual PBPs in transglycosylation and transpeptidation remains controversial. Although the nucleotide sequence of PBP2 suggests that it has bifunctionality (30) , it has been reported that the transglycosylase activity is not associated with the transpeptidase activity in S. aureus (35) .
Known inhibitors of bacterial cell wall biosynthesis target various stages of this process. Cycloserine and fosfomycin inhibit the formation of cytoplasmic precursors (23, 25, 44) . Bacitracin inhibits the recycling of the undecaprenol carrier and consequently blocks the formation of lipid I (42, 43) . Ramoplanin blocks the conversion of lipid I to lipid II (40) and, as proposed recently (27, 28) , might sequester lipid II and thereby inhibit transglycosylation as well. Most of the known inhibitors of the transglycosylation reaction, including glycopeptides (vancomycin, teicoplanin) and lantibiotics (nisin, mersacidin), act by binding to lipid II, the substrate of transglycosylase (10, 12, 36) . However, moenomycin interacts directly with transglycosylase (50) . Penicillin and other ␤-lactam antibiotics are inhibitors of transpeptidation (7) . The later stages of cell wall biosynthesis and the steps inhibited by various antimicrobial agents are shown in Fig. 1 .
Because of the emergence of resistance to many of the existing antibiotics, a search for new cell wall-specific inhibitors continues. The mannopeptimycins are novel glycopeptide antibiotics that were originally isolated as a complex of five nat-ural products (mannopeptimycins ␣ through ε, formerly known as AC98-1 through AC98-5, respectively) from a strain of Streptomyces hygroscopicus, LL-AC98 (18) . Subsequently, various semisynthetic modifications that enhanced the antibacterial properties were made; among the most promising derivatives is AC98-6446, an accessible ketal derivative of a modified mannopeptimycin core (Fig. 2) other glycopeptide antibiotics in that they target cell wall biosynthesis, more specifically, the transglycosylation reaction (13, 39) . However, the activity of the mannopeptimycins against vancomycin-resistant organisms indicated that they might have a unique mode of action. The aim of the present study was to investigate the mechanism of antimicrobial activity of the mannopeptimycins.
MATERIALS AND METHODS
Bacterial strains and growth conditions. S. aureus ATCC 29213, S. aureus Smith, and E. coli ATCC 25922 were used in this study and are well-characterized reference strains. Staphylococcus epidermidis PT 5036 is a clinical isolate. S. aureus 12873-10 was described previously and has increased resistance to both vancomycin and teicoplanin (37) . Bacterial cells were grown in either brain heart infusion broth (BHI) or Trypticase soy broth (TSB) at 37°C with aeration.
Chemicals. The following commercially available compounds were purchased from the indicated manufacturers: UDP-[
14 C]GlcNAc (250 mCi/mmol) from American Radiolabeled Chemicals, Inc.; vancomycin, pentapeptide (Ala-D-␥-Glu-Lys-D-Ala-D-Ala), UDP-GlcNAc, and lipoteichoic acid (LTA) of S. aureus from Sigma; and BHI and TSB from Difco Laboratories. Mersacidin was kindly provided by Hans-Georg Sahl. Ramoplanin was kindly provided by Franco Parenti. Mannopeptimycin-␦, AC98-3189, [ 3 H]AC98-3189, AC98-0708, AC98-4800, AC98-5370, and AC98-6446 were used in this study. They were synthesized at Wyeth Research and have been described previously (Dushin et al., 42nd ICAAC). Mannopeptimycin-␦ and AC98-4800 (mannopeptimycin aglycone) have been described previously (18) .
Selection and synthesis of a mannopeptimycin photoaffinity probe. To facilitate the study of the mechanism of action of the mannopeptimycins, a radiolabeled benzophenone (BP)-based photoaffinity probe was prepared. BP derivatives are excited upon exposure to long-wave (350-to 360-nm) UV light and preferentially form covalent bonds with unreactive CH groups in the biological target. A radiolabeled BP derivative was chosen with the assumption that the BP moiety would form cross-links between the probe molecule and its biological target in a relatively lipophilic environment (1, 3, 14, 47) . BP affinity probes have been used to label targets within membranes (16, 17) , while BP moieties linked through acetal functionality have previously been reported in the context of steroids (24) . Hence, a BP moiety was attached to mannopeptimycin-␣ via an acetal linkage. The resulting derivative, AC98-3189 ( Fig. 2) , had good antibacterial activity (MIC for S. aureus, 0.5 to 2 g/ml). A complete description of the preparation of this material will be reported elsewhere (R. G. Dushin, A. G. Sutherland, A. Minnick, and M. May, unpublished data).
PBP-binding competition assay. The cell membranes from S. aureus ATCC 29213 and E. coli ATCC 25922 used in the PBP assays were prepared as described previously (41, 56) , with the exception that a glass-bead cell disrupter instead of sonication was used to break the cells. An overnight bacterial culture of S. aureus ATCC 29213 in BHI was diluted 1:100 in 8 liters of BHI, grown with shaking to an A 600 of 0.6, and centrifuged. The cell pellet was washed twice in 200 ml of sonication buffer (50 mM Tris-HCl [pH 8.0], 1 mM MgCl 2 ) and was resuspended in 100 ml of lysis buffer (sonication buffer supplemented with 2 mM ␤-mercaptoethanol). The cells were broken with a glass-bead cell disrupter by using 0.1-mm-diameter glass beads (Biospec Products, Bartlesville, Okla.); and the unbroken cells, cell debris, and beads were removed by centrifugation at 3,600 ϫ g for 10 min, followed by two additional centrifugations at 9,300 ϫ g for 20 min each. The supernatant was then subjected to ultracentrifugation (30 . The pellet (membrane fraction) was then resuspended in 4 ml of lysis buffer and passed several times through an 18-gauge needle to obtain a homogeneous suspension. In the competition assay, the solubilized membranes were incubated with different concentrations of mannopeptimycin-␦ and control antibiotics for 10 min at 30°C. Aliquots (10 l) of [ 3 H]benzylpenicillin were then added, and the mixture was incubated for an additional 10 min. The reaction was terminated by the addition of 500 l of cold acetone. The precipitated protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (PAGE), followed by fluorography, as described previously (56) .
Competition of soluble pentapeptide for mannopeptimycin-␦. A competitive binding bioassay was performed by previously described methods (5), except that S. aureus 12873-10 was used as the indicator organism (38) . The pentapeptide Ala-D-␥-Glu-Lys-D-Ala-D-Ala, vancomycin, and mannopeptimycin-␦ were diluted in water and mixed in fixed pentapeptide-to-glycopeptide molar ratios of 0:1, 5:1, 2.5:1, 1:1, 0.5:1, and 0.25:1. Following inoculation of the organism onto a square bioassay plate (245 by 245 mm) containing Mueller-Hinton agar (BBL), 20 l of each mixture was spotted onto sterile filter paper disks. Each mixture was tested in quadruplicate. The plate was incubated overnight at 37°C, and the zone diameter (in millimeters) was measured and recorded.
Isolation of PG nucleotide precursors from S. aureus. The pool of cytoplasmic UDP-linked PG precursors was extracted by a modification of a previously described method (34) . S. aureus Smith was grown to mid-logarithmic phase in either TSB or TSB supplemented with AC98-6446 (final concentration, 2 g/ml), chilled, harvested by centrifugation, washed in 0.9% NaCl, and extracted with cold trichloroacetic acid (final concentration, 5%) for 30 min at 4°C. The extract was desalted on a Sephadex G-25 column and concentrated by rotary evaporation. High-pressure liquid chromatography (HPLC) separation of the precursors was performed essentially by the method of Flouret et al. (15), with some modifications. The precursors were separated by reverse-phase HPLC on a Bondapak C 18 column (3.9 by 300 mm; Waters) in 50 mM ammonium formate (pH 3.9) at a flow rate of 0.5 ml/min. Elution of the precursors was monitored at 254 nm. The peak corresponding to UDP-MurNAc-pentapeptide was harvested, and its identity was confirmed by electrospray ionization mass spectrometry with a Micromass Q-ToF mass spectrometer equipped with a nanoelectrospray source.
Isolation of PG nucleotide precursors from S. epidermidis. Cytoplasmic PG precursors were extracted and purified from S. epidermidis PT 5036 by a previously described method (6, 8) . S. epidermidis PT 5036 was grown to mid-logarithmic phase either in BHI or in BHI supplied with mannopeptimycin-␦ (final concentration, 8 g/ml) and was then harvested by centrifugation at 8,000 ϫ g for 10 min. Cytoplasmic PG precursors were extracted with 1.1 M formic acid on ice for 30 min and were then centrifuged at 15,000 ϫ g for 20 min at 4°C. The supernatant was collected and neutralized to pH 8.0 with NH 4 OH. The precursors were then purified by three cycles of lyophilization followed by chromatography on a Sephadex G-25 column. Fractions were eluted with water at 4°C, monitored at 262 nm, and then pooled and lyophilized. The sample was then analyzed by HPLC with an isocratic mobile phase consisting of 70% buffer A (10 mM CH 3 COOHNH 4 [pH 5.0]) and 30% buffer B (2% acetonitrile). The identity of UDP-MurNAc-pentapeptide was confirmed by electrospray ionization mass spectrometry analysis with a Micromass Q-ToF mass spectrometer equipped with a nanoelectrospray source.
PG biosynthesis in vitro. The biosynthesis of PG in vitro, which yields both lipid II and PG, was performed as described previously (2, 40) , with some modifications, including the addition of 0.1% Triton X-100 to the reaction mixture and preincubation of the membranes both prior to the addition of UDP-MurNAc-pentapeptide (30 min on ice) and prior to the addition of UDP-[ 14 C]GlcNAc (10 min, room temperature). The procedure used for the preparation of cell membranes for thin-layer chromatography (TLC) was identical to the procedure described above for the PBP-binding assay. The reaction mixture contained 0.05 M Tris-HCl (pH 7.8), 10 mM MgCl 2 , and 0.1% Triton X-100 in a final volume of 14 l; cell membranes (20 g of protein); 33 M UDPMurNAc-pentapeptide; and 5.7 M either UDP-GlcNAc or UDP-[
14 C]GlcNAc. When required, the samples were preincubated with either various concentrations of mannopeptimycin-␦ or 50 g of ramoplanin per ml for 10 min at room temperature prior to the addition of UDP-[
14 C]GlcNAc. Upon the addition of all reagents, the reaction mixture was incubated for 30 min at room temperature and was then placed into a boiling-water bath for 2 min to inactivate the enzymes, thus preventing degradation of lipid II. Aliquots (2 l) of the samples were separated by TLC on silica gel plates (K6; Whatman) for 2 h in isobutyric acid-1 M NH 4 OH (5:3; vol/vol). After separation, the plates were dried and exposed to X-ray film (BioMax MS; Kodak).
Preparative TLC and extraction of lipid II. Preparative quantities (200 l) of both unlabeled and 14 C-labeled samples from the in vitro PG biosynthesis reactions were applied to a preparative TLC plate (PK6F; Whatman) and separated as described above. The 14 C-labeled sample was applied on both sides of the plate to serve as a marker for lipid II isolation. After separation, the plates were dried and exposed to X-ray film (BioMax MS; Kodak). The area of silica gel containing lipid II was identified by matching of the gel with an autoradiographed standard and was scraped off the plate. Lipid II was extracted from the silica gel with 30 ml of a mixture of 90% (vol/vol) methanol and 10% (vol/vol) acetic acid, followed by incubation for 5 min at room temperature on a rotating platform (100 rpm). The silica gel was removed by centrifugation at 3,000 ϫ g for 5 min and was extracted twice more under identical conditions. The supernatants were combined in a 500-ml round-bottom flask and concentrated to the minimal possible volume under vacuum on a rotary evaporator (Bü chi; Flawil, Switzerland). The volume was brought up to 30 ml with methanol, and the mixture was evaporated again. This procedure was repeated seven times to minimize traces of acetic acid. The resulting pellet was redissolved in 30 ml of methanol, transferred to a 50-ml conical flask, and evaporated to dryness. The new pellet was dissolved in 600 l of methanol, centrifuged at 13,000 ϫ g for 1 min to remove fine silica gel particles, and used for subsequent experiments. As judged by extraction of To cross-link the photoaffinity moiety to lipid II, reaction mixtures (total volume, 10 l) were transferred to individual wells of a 96-well polypropylene plate, and the plates were incubated for 10 min at 30°C and exposed to long-wave (wavelength, 350 to 360 nm) UV light for 30 min on ice. The samples were separated by TLC on silica gel plates (K6; Whatman) as described above. After separation, the plates were dried and exposed to X-ray film (BioMax MS; Kodak) for 10 to 14 days. Spot densitometry of the autoradiographs was performed by using a GS-710 densitometer (Bio-Rad).
Gel-based binding assay. A gel-based mannopeptimycin-lipid II binding assay was developed by modification of a previously described assay (12) . Various amounts (from 0 to 10 l) of the lipid II TLC extract mentioned above were placed in glass tubes (12 by 35 mm) and evaporated to dryness by gentle airflow. The dried samples were preincubated with different amounts of various competing drugs in 50 mM Tris-HCl (pH 7.5)-1 mM MgCl 2 buffer for 10 min at 30°C. [ 3 H]AC98-3189 was added to each tube, and the tubes were incubated again for 10 min at 30°C. Glycerol and bromophenol blue were added prior to electrophoresis. In addition to lipid II (with no lipid II included in the control sample), a typical sample contained 15 l of buffer, 5 l of competing drug solution (various concentrations), 125 ng of [ 3 H]AC98-3189 (5 l of a 25-g/ml solution), and 6 l of a mixture of 50% glycerol and 0.125% bromophenol blue. Samples were subjected to nondenaturing PAGE on an 18% polyacrylamide gel (Novex). Following electrophoresis, the gel was treated with an autoradiography enhancer (Entensify; New England Nuclear Corp., Boston, Mass.) according to the instructions of the manufacturer, dried, and exposed to X-ray film (X-OMAT AR; Kodak) for 2 days at Ϫ70°C.
RESULTS

Effect of mannopeptimycins on PG biosynthesis.
Treatment with mannopeptimycin-␦ caused the accumulation of UDPMurNAc-Ala-Glu-Lys-Ala-Ala (referred to as UDP-MurNAcpentapeptide) in S. epidermidis strain PT 5036 (Fig. 3A) . On the basis of the peak area, there was at least a 30-fold increase in the amount of UDP-MurNAc-pentapeptide in mannopeptimycin-␦-treated cells compared with the amount in untreated cells. Similarly, the more active mannopeptimycin, AC98-6446 (Fig. 2) , caused the accumulation of UDP-MurNAc-pentapeptide in S. aureus Smith (Fig. 3B) . These results indicate that the cytoplasmic enzymes MurA through MurF are not affected and that the mannopeptimycins most likely impair cell wall biosynthesis at the time of or after the formation of the undecaprenol-bound intermediates, lipid I and lipid II. The data pre- . The peak that corresponds to UDP-MurNAc-pentapeptide is marked by an asterisk. (B) HPLC profile of cytoplasmic UDP-linked PG precursors isolated from S. aureus Smith that was grown either in the absence (a) or in the presence (b) of AC98-6446 (final concentration, 2 g/ml). The peak that corresponds to UDP-MurNAc-pentapeptide is marked by an asterisk. sented in Fig. 4 confirm the results of the experiments performed by DeCenzo et al. (13) and show that, like ramoplanin, the mannopeptimycins inhibit PG formation. However, in contrast to ramoplanin, the mannopeptimycins have no effect on the formation of lipid II. This suggests that the mannopeptimycins act on one of the final steps of PG synthesis, such as transglycosylation or transpeptidation, or both. A competition PBP-binding assay with labeled benzylpenicillin showed that mannopeptimycin-␦ does not bind to any of the staphylococcal or E. coli PBPs (data not shown). In contrast, ampicillin, imipenem, and aztreonam, the ␤-lactam antibiotics with known affinities for specific PBPs, showed reduced levels of binding of the labeled benzylpenicillin. This suggests that mannopeptimycin-␦ does not bind to the transpeptidation domain of classical PBPs and favors the hypothesis that the mannopeptimycins, similar to vancomycin, most likely target transglycosylation rather than the transpeptidation reaction. Fig. 6A , part of the labeled mannopeptimycin migrated into the gel in the presence of lipid II (lower band), while another part precipitated into the well (upper band). Neither of these signals was detected in the absence of lipid II, indicating that the lipid II-mannopeptimycin interaction is the reason that these additional two bands were observed. The intensity of the lower band was dependent on the concentrations of both lipid II and [ 3 H]AC98-3189, was decreased in the presence of AC98-3189, and was unaffected by the addition of either vancomycin or mersacidin in a competition-type assay (Fig. 6A) . The intensity of the lower band was not antagonized by the addition of various compounds that represent or mimic parts of lipid II, such as UDP-MurNAc-pentapeptide, MurNAc, and GlcNAc; and these compounds did not cause entry of 3 H]AC98-3189-cell membrane mixture was exposed to long-wave UV light to cross-link the BP group. The mixture was then separated by TLC. As shown in Fig. 6B , in the absence of the membrane preparation, the labeled mannopeptimycin was detected as one band, whereas in the presence of the membrane preparation, (Fig. 6B) . In addition, the upper retarded species was not observed with the membranes that were depleted of lipid II by treatment with ramoplanin (Fig. 6B) . In contrast, treatment with ramoplanin did not affect the retention of [ 3 H]AC98-3189 at the TLC baseline (Fig. 6B) .
The retention of a portion of radiolabeled mannopeptimycin on the baseline observed with membranes might possibly suggest an interaction with some high-molecular-weight membrane-bound compound(s). Among possible candidates for mannopeptimycin binding are LTA and nascent teichoic acid (TA), both of which contain multiple negatively charged phosphate groups that might interact electrostatically with the positively charged amino groups of the mannopeptimycins. Treatment of the membranes with both proteinase K and muramidase had no effect on mannopeptimycin binding (data not shown). Therefore, it is unlikely that other membranebound substances such as proteins or nascent PG contribute significantly to the interaction with the mannopeptimycins.
Competition assay with mannopeptimycins and binding of mannopeptimycin to LTA. In order to determine whether the binding of mannopeptimycins to lipid II is related to their antimicrobial activity, several mannopeptimycins with different MICs were tested for their ability to compete with [ Fig. 7B , the antimicrobial activities of the mannopeptimycins (MICs) correlated with their affinities for lipid II (50% inhibitory concentrations), which further supports the hypothesis that lipid II serves as a primary target for the mannopeptimycins. In contrast, the amount of [ 3 H]AC98-3189 retained on the baseline TLC was not significantly affected by the most active mannopeptimycin, AC98-6446 (Fig. 7C) , suggesting that the binding of the mannopeptimycins to membrane components other than lipid II is rather nonspecific.
To test whether the mannopeptimycins interact with LTA, LTA was used in the aforementioned gel-based binding and TLC-based competition assays. As shown in Fig. 8A , the presence of LTA resulted in the entry of (Fig. 8B) , supporting the notion that the interaction between the mannopeptimycins and lipid II has a higher affinity than that between the mannopeptimycins and LTA.
DISCUSSION
The ability of the mannopeptimycins to inhibit the growth of a wide range of gram-positive pathogens, including those resistant to methicillin and vancomycin, provided the incentive for the mechanism-of-action studies described here. The results obtained in this study indicate that the mannopeptimycins inhibit PG synthesis by blocking the transglycosylation reaction. It was demonstrated that the mannopeptimycin [ 3 H]AC98-3189 bound to both the isolated and the membranebound PG precursor, lipid II, and that the affinity of this interaction correlated with the antimicrobial activities of other mannopeptimycins. This suggests that, similar to other glycopeptide antibiotics, such as vancomycin and teicoplanin, the lantibiotic mersacidin, and likely, ramoplanin, the mannopeptimycins inhibit transglycosylase by binding to its substrate rather than by binding to the enzyme itself.
It should be noted that the extraction of lipid II from TLC plates described in this study did not yield 100% pure lipid II, as has been the case for other lipid II purification protocols based on radioactivity tracing (48, 52) . It has been reported that traces of other lipids, particularly lipid I, are present in the final preparations of lipid II (48, 52) . Therefore, the results of the experiments, which were performed with partially purified lipid II, did not exclude the possibility that the mannopeptimycins might interact with lipid I and/or other membrane lipids. However, the addition of ramoplanin, a known inhibitor of lipid II biosynthesis that does not affect the formation of lipid I (40) , eliminated the upper retarded species in the TLC binding assay (Fig. 6B) , suggesting that the mannopeptimycins primarily interact with lipid II.
It was also demonstrated that, in addition to lipid II, [ 3 H]AC98-3189 interacts with LTA. It is likely that the mannopeptimycin-LTA interaction is of an electrostatic nature due to the presence of multiple negatively charged phosphate groups in TAs. This finding might point to some additional inhibitory effects of the mannopeptimycins. The biosyntheses of both TA and LTA are linked, as LTA serves as an alanyl donor for TA and is reported to act as an LTA carrier involved in the transfer of ribitol phosphate (26) . It is possible that by binding to LTA, the mannopeptimycins interfere with the proper transfer of functional groups from the LTA carrier to TA and as a result block TA biosynthesis. Another possibility is that the mannopeptimycins might act similarly to the lantibiotics nisin and Pep5, which disrupt the electrostatic interactions between autolytic enzymes and LTA, resulting in cell lysis (4) . Alternatively, either LTA or TA, or both, might serve as the initial binding site(s) for the mannopeptimycins, which could allow the accumulation of antibiotic on the bacterial cell surface and promote a specific mannopeptimycin-lipid II interaction.
It was shown that the addition of soluble pentapeptide does not affect the antimicrobial activity of mannopeptimycins and that vancomycin does not compete with mannopeptimycin for lipid II binding ( Fig. 5 and 6A ). This ruled out the involvement of the pentapeptide portion of lipid II in the mannopeptimycin-lipid II interaction and might explain the activity of the mannopeptimycins against vancomycin-resistant organisms. Mannopeptimycins might interact with other components of lipid II, such as the disaccharide unit of MurNAc-GlcNAc and the pyrophosphate moiety. Both of these groups were proposed to be binding sites for another lipid II-binding antibiotic, mersacidin (12) . However, mersacidin does not compete with the mannopeptimycins for lipid II binding, indicating that these two antibiotics might recognize lipid II differently as well.
This hypothesis is perhaps supported by the fact that the mannopeptimycins are active against the mersacidin-producing organism, a Bacillus sp. (data not shown). Alternatively, the lack of an effect of mersacidin on mannopeptimycin-lipid II binding might result from a higher affinity of the mannopeptimycins toward lipid II, which would not preclude at least a partial overlap in the binding sites of these two antibiotics. Additional experiments are required to determine the exact sites involved in the mannopeptimycin-lipid II interaction.
